200 related articles for article (PubMed ID: 23594438)
1. The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2).
Bruserud Ø
Toxins (Basel); 2013 Apr; 5(4):665-74. PubMed ID: 23594438
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of platelet aggregation by affinity captured rhodocytin from the Malayan pit viper Calloselasma rhodostoma.
Feickert MK; Sanz-Soler R; Niland S; König S; Eble JA; Obermann WMJ
Toxicon; 2023 Mar; 225():107058. PubMed ID: 36806336
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC-2.
Watson AA; O'Callaghan CA
Toxins (Basel); 2011 Aug; 3(8):991-1003. PubMed ID: 22069753
[TBL] [Abstract][Full Text] [Related]
5. Thrombomodulation via CLEC-2 targeting.
O'Callaghan CA
Curr Opin Pharmacol; 2009 Apr; 9(2):90-5. PubMed ID: 19091630
[TBL] [Abstract][Full Text] [Related]
6. Snake venom rhodocytin induces plasma extravasation via toxin-mediated interactions between platelets and mast cells.
Nakamura Y; Sasaki T; Mochizuki C; Ishimaru K; Koizumi S; Shinmori H; Suzuki-Inoue K; Nakao A
Sci Rep; 2019 Nov; 9(1):15958. PubMed ID: 31685912
[TBL] [Abstract][Full Text] [Related]
7. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.
Nagae M; Morita-Matsumoto K; Kato M; Kaneko MK; Kato Y; Yamaguchi Y
Structure; 2014 Dec; 22(12):1711-1721. PubMed ID: 25458834
[TBL] [Abstract][Full Text] [Related]
8. Venomics of Calloselasma rhodostoma, the Malayan pit viper: A complex toxin arsenal unraveled.
Tang EL; Tan CH; Fung SY; Tan NH
J Proteomics; 2016 Oct; 148():44-56. PubMed ID: 27418434
[TBL] [Abstract][Full Text] [Related]
9. The novel platelet activation receptor CLEC-2.
Suzuki-Inoue K; Inoue O; Ozaki Y
Platelets; 2011; 22(5):380-4. PubMed ID: 21714702
[TBL] [Abstract][Full Text] [Related]
10. A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation.
Parguiña AF; Alonso J; Rosa I; Vélez P; González-López MJ; Guitián E; Eble JA; Loza MI; García Á
Blood; 2012 Dec; 120(26):e117-26. PubMed ID: 23053573
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
[TBL] [Abstract][Full Text] [Related]
13. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
14.
Tan CH; Tan KY; Ng TS; Tan NH; Chong HP
Toxins (Basel); 2023 Apr; 15(5):. PubMed ID: 37235350
[TBL] [Abstract][Full Text] [Related]
15. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
Suzuki-Inoue K
J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
[TBL] [Abstract][Full Text] [Related]
16. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.
Suzuki-Inoue K; Osada M; Ozaki Y
J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2.
Watson AA; Eble JA; O'Callaghan CA
Protein Sci; 2008 Sep; 17(9):1611-6. PubMed ID: 18583525
[TBL] [Abstract][Full Text] [Related]
18. A change of rhodocytin's suprastructure turns the agonist into an antagonist of tumor cell induced platelet aggregation.
Obermann WMJ; König S; Feickert MK; Sanz-Soler R; Eble JA
FASEB J; 2024 Jan; 38(2):e23402. PubMed ID: 38193585
[TBL] [Abstract][Full Text] [Related]
19. New binding face of C-type lectin-like domains.
Fukuhara H; Furukawa A; Maenaka K
Structure; 2014 Dec; 22(12):1694-1696. PubMed ID: 25470427
[TBL] [Abstract][Full Text] [Related]
20. Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha.
Bergmeier W; Bouvard D; Eble JA; Mokhtari-Nejad R; Schulte V; Zirngibl H; Brakebusch C; Fässler R; Nieswandt B
J Biol Chem; 2001 Jul; 276(27):25121-6. PubMed ID: 11352922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
